亚洲人和白人患者之间心力衰竭的药理干预与减少喷射率的比较有效性:随机对照试验的元分析

相关实验视频

Updated: Sep 8, 2025

07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

Wenxi Huang¹, Huilin Tang¹, Yujia Li¹

¹Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, 1889 Museum Road, DSIT 6004, Gainesville, FL, 32606, USA.

American journal of cardiovascular drugs : drugs, devices, and other interventions

|July 11, 2025

概括

在亚洲和白人患者中,-葡萄糖共运输体2 (SGLT2) 抑制剂有效地降低了心力衰竭的不良结果,降低了排气分数 (HFrEF). 这种治疗在亚洲人群中显示出更明显的益处,这强调了在高频管理中考虑种族因素的重要性.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
公共卫生公共卫生

背景情况:

心力衰竭 (HF) 不成比例地影响亚洲人群,与其他群体相比,在较年轻时出现.
对于有效的公共卫生策略来说,了解HF治疗疗效的种族差异至关重要.

研究的目的:

为了比较各种药理干预治疗心力衰竭的有效性,在亚洲患者和白人患者中减少排气分数 (HFrEF).
在HFrEF管理中,考虑到种族和民族差异,确定最佳的治疗方法.

主要方法:

研究人员对随机对照试验 (RCT) 进行了一项对照的元分析,涉及HFrEF的成年患者.
在Embase,PubMed和Cochrane数据库中搜索到2022年2月为HF药物的RCT.
主要结局:包括HF住院,心血管死亡和全因死亡率.

主要成果:

-葡萄糖共运输体2 (SGLT2) 抑制剂在亚洲患者中最有效 (RR 0.61),在白人患者中第二有效 (RR 0.72).
贝塔抑制剂在白人患者中最有效 (RR 0.68).
总的来说,SGLT2抑制剂在减少HFrEF患者的不良结果方面表现最为有效,亚洲人的效果明显更好 (P_interaction=0.014).

结论:

SGLT2 抑制剂有效地减少了亚洲人和白人的HFrEF患者的不良临床结果.
在亚洲人群中观察到SGLT2抑制剂的治疗效果更为明显.
在心力衰竭的临床治疗中,必须考虑种族和民族差异.

相关概念视频

01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

505

01:22

Heart Failure Drugs: β-Blockers

434

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

434

01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...